Yeztugo (lenacapavir) is an HIV-1 capsid inhibitor that is administered every 6 months after an initial dosing regimen.

The decline has been attributed to HIV prevention efforts such as federally funded free HIV testing, STD Screening and community education around infections. The Los Angeles County Department of ...

The Statistical Center for HIV/AIDS Research and Prevention (SCHARP), located at Fred Hutch Cancer Center, is a statistical and data management center (SDMC) dedicated to supporting investigators who ...

In a study of human immune cells infected with HIV, the virus that causes AIDS, scientists at Johns Hopkins Medicine say a ...

Lenacapavir, created by Foster City-based Gilead Sciences, has been in use for several years as a treatment for HIV/AIDS ...

It can take HIV symptoms years to appear—sometimes even longer—after infection. But within a month or two of HIV entering the body, 40% to 90% of people experience symptoms known as acute retroviral ...

The US Food and Drug Administration (FDA) has approved lenacapavir, an injectable drug that offers long-lasting protection ...

Gilead Sciences, Inc. GILD obtained FDA approval for its twice-yearly injectable HIV-1 capsid inhibitor, lenacapavir, for the ...

Meanwhile, 1,583 cases of HIV were recorded between January and December last year, with 90.3 percent of the cases being iTaukei. This is equivalent to 1,430 individuals.

Many rapid HIV tests deliver results in 30 minutes or fewer. Discover the best time to test, other at-home tests, next steps after testing, and more.

Women widowed by AIDS or living with HIV may face property disputes with in-laws, complicated by limited access to justice to uphold their rights. Regardless of whether they themselves are living with ...

In 2016, of the total estimated 1.7 million new HIV infections among adults (15 and older) globally, 790,000 or 48 per cent were among women . 59 per cent of new HIV infections among young persons ...